Quantcast

Calypso Medical’s Real-Time Tracking Technology in Radiation Therapy Highlighted in 23 Clinical Presentations at the 50th Annual ASTRO Scientific Sessions

September 20, 2008

Calypso Medical Technologies, Inc. today announced that 23 abstracts highlighting the use of the Calypso(R) 4D Localization System(TM) will be presented this week at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) at the Boston Convention and Exhibition Center. The studies report on a wide range of benefits of the Calypso System.

The Calypso System is the only real-time target tracking system used to manage tumor motion during treatment delivery. The ability to manage motion during radiation therapy is a critical advancement that assures the clinician and the patient that the radiation treatment prescribed is delivered to the cancerous tissue while avoiding adjacent healthy organs. Known as GPS for the Body(R), the Calypso System utilizes implanted Beacon(R) electromagnetic transponders, smaller than a grain of rice, to enable continuous tracking of the prostate during radiation treatment.

The results of a study entitled “Geometric Accuracy and Latency of an Integrated 4D IMRT Delivery System Using Real-Time Internal Position Monitoring and Dynamic MLC (multileaf collimator) Tracking” will be presented by Dr. Amit Sawant of Stanford University. Dr. Sawant’s research focuses on using dynamic MLC technology to respond to respiratory motion during therapy. This research demonstrates that the Calypso System is capable of guiding the delivery of radiation to moving tumors with sub-millimeter accuracy by tracking a target in real-time.

A significant amount of research has been performed assessing the utility of the Calypso System in managing prostate motion. Among the highlights is a study (“Prostate Patient Setup Error and Organ Motion Error for Conventional and Hypo-Fractionated Radiation Therapy”) by Dr. Zhong Su, et al., demonstrating the high probability of inter-fraction set-up errors that could be eliminated with Calypso-guided online setup. Dr. J. R. Olson, et al., in “Individual Margin Determination for Prostate Cancer Patients Undergoing Real-Time Tracking” showed the importance of monitoring patient-specific rotation because it can lead to inadequate PTV coverage.

The importance of real-time tracking was also evaluated in new clinical areas. The results of a study conducted by Dr. M. L. Mayse, et al., entitled “Development of a Non-Migrating Electromagnetic Transponder System for Lung Tumor Tracking” showed the feasibility of using stabilized transponders in the lung. The potential of using transponders to monitor lung motion could prove to be an essential factor in lung cancer radiation therapy management. In “Feasibility of AC Electromagnetic Localization for External Beam Partial Breast Irradiation” by Dr. Stephen Eulau, et al., the Calypso System was used to localize and continuously track the lumpectomy cavity during partial breast radiation therapy. The authors concluded Calypso’s technology provides an efficient means to correct setup errors and manage intrafractional motion, even after couch kicks. In addition, they pointed out that continuous tracking could potentially enable the use of tighter treatment margins.

“It is very encouraging to see the large and growing body of scientific work demonstrating the many advantages of the Calypso System,” said Eric R. Meier, CEO and President of Calypso Medical. “As the evidence shows, continuously tracking the position of the prostate or other vital organs during radiation treatment provides clear clinical benefits for physicians and their patients.”

 Geometric Accuracy and Latency of an Integrated Intrafraction Motion Management System Using Real-Time Internal Position Monitoring and Dynamic MLC Tracking Amit Sawant, et al., Stanford University, Palo Alto, Calif. Monday, Sept. 22nd, 11:35 a.m., Room 258.  Prostate Displacement During and After Transabdominal Ultrasound (US) Guidance, Monitored by a Real-Time Tracking System B. J. Salter, B. Wang, M. Szegedi, J. D. Tward, D. C. Shrieve, Huntsman Cancer Institute, Salt Lake City, Utah. Tuesday, Sept. 23rd, 1:45-3:15 p.m., Room 157.  Gains from Real-Time Prostate Motion Monitoring During External Beam Radiation Therapy J. Li, L. Jin, E. Horwitz, A. Pollack, S. Johnston, R. Price Jr., and C. Ma, Fox Chase Cancer Center, Philadelphia, Pa. #2265.  Daily Isocenter Correction During Prostate Radiotherapy (RT) Helps to Avoid Significantly Decreased Target Volume Dose and Increased Rectal Dose R. R. Rajendran, D. L. McMichael, A. Kassaee, J. P. Plastaras, N. Vapiwala, University of Pennsylvania Medical Center, Philadelphia, Pa. #2267.  Bevacizumab in Combination with Androgen Deprivation and IMRT in Patients with High Risk Prostate Cancer H. T. Pham, S. Warren, R. A. Hsi, B. L. Madsen, G. S. Song, K. R. Badiozamani, J. Vuky, Virginia Mason Medical Center, Seattle, Wash. #2281.  Clinically Useful Observations of Prostate Motion Using Calypso(R) 4D Localization System Jay Shelton, MD; Tomi Ogunleye, MS; Ashesh B. Jani, MD, M.S.E.E.; Eric Elder, PhD; Peter J. Rossi, MD, Emory University School of Medicine, Atlanta, Ga. #2291.  Evaluation of Interfraction and Intrafraction Prostate Motion During the Treatment of Prostate Cancer Using the Calypso 4D Localization System R. A. Hsi, F. Vali, H. Parsai, E. Garver, B. Madsen, H. Pham, G. Song, K. Badiozamani, P. Cho, Virginia Mason Medical Center, Seattle, Wash. #2292.  A Phase II Trial of Trilogy-Based Prostate SBRT: Report of Favorable Toxicity and Early Biochemical Outcomes Constantine Mantz, MD; Eduardo Fernandez, MD; Steven Harrison, MD; Ira Zucker, MD, 21st Century Oncology, Fort Myers and Plantation, Fla. #2317.  Quantifying Respiratory-Induced Prostate Motion Using Continuous Real-Time Tracking Technology T. L. McDonald, L. Ku, K. M. O'Donnell, D. Kaurin, P. J. Gagnon, C. R. Thomas, A. Y. Hung, M. Fuss, Oregon Health & Science University, Portland, Ore. #2369.  Non-Gaussian Nature Of Prostatic Motion Using Real-Time Tracking and Its Impact on Treatment Margins M. K. Khan, A. M. Mahadevan, Q. Chen, Cleveland Clinic, Cleveland, Ohio. #2374.  Real-Time Prostate Motion is Highly Variable Among Patients Undergoing Prostate Radiotherapy (RT) with Electromagnetic Localization and Tracking N. Vapiwala, R. R. Rajendran, J. P. Plastaras, A. Kassaee, University of Pennsylvania Medical Center, Philadelphia, Pa. #2405.  Development Of A Non-Migrating Electromagnetic Transponder System For Lung Tumor Tracking M. L. Mayse, R. L. Smith, M. Park, G. H. Monteon, E. H. Silver, P. J. Parikh, E. Nielson, D. L. Misselhorn, M. R. Talcott, S. Dimmer, et al., Washington University School of Medicine, St. Louis, Mo. #2584.  Feasibility of AC Electromagnetic Localization for External Beam Partial Breast Irradiation Stephen Eulau, Astrid Morris, Paula Hallam, Muhammad Afghan, Jin- Song Ye, Tricia Zeller, Timothy Mate, Swedish Cancer Institute, Seattle, Wash. #2783.  Impact of Localization Technique on the Accuracy of Daily Repositioning of Prostatic Isocenter During Radiotherapy T. He, D. G. Kaurin, J. Tanyi, J. Wu, W. D'Souza, M. Fuss, A. Hung, Oregon Health Sciences University, Portland, Ore. #2840.  Prostate Gland Motion in Prone and Supine Positions Assessed in Real-Time by Implanted Electromagnetic Transponders Wayne M. Butler, PhD; Brian S. Kurko, MS; Brian C. Murray, BS; and Gregory S. Merrick, MD, Schiffler Cancer Center, Wheeling Hospital, W.Va. #2861.  Automatic Deformable Registration on Prostate Cine-MRI Images for Studying Intra-Fraction Motion in Supine and Prone Position with and without Rectal Balloon W. C. Hsi, C. Vargas, A. Saito, J. F. Dempsey, S. Keole, L. Lin, S. Flampouri, Z. Li, J. Palta, Florida Proton Therapy Institute, Jacksonville, Fla. #2866.  Prostate Patient Setup and Organ Motion Error for Conventional and Hypo-Fractionated Radiation Therapy Zhong Su, Yousaf Falukhi, Martin Murphy and Jeff Williamson, Virginia Commonwealth University, Richmond, Va. #2890.  Individual Margin Determination for Prostate Cancer Patients Undergoing Real-Time Tracking Jeff Olsen, Camille Noel, Lakshmi Santanam, Jeff Michalski, Parag Parikh, Washington University School of Medicine, St. Louis, Mo. #2904.  Dosimetric Influence of Intrafraction Prostate Motion on IMRT Treatment with Sliding Window Dynamic Mulitleaf Collimator Technique W. Fu, Y. Yang, N. J. Yue, R. Selvaraj, A. Chen, K. Mehta, D. E. Heron, M. S. Huq, University of Pittsburgh Cancer Institute, Pittsburgh, Pa, The Cancer Institute of New Jersey, New Brunswick, N.J. #2910.  IMRT Dosimetric Measurements from a Real-Time Internal Position Monitoring System Coupled with a Dynamic Multileaf Collimator Tracking System Ryan L. Smith, et al., Washington University School of Medicine, St. Louis, Mo. #2988.  The Effect of Transponder Motion on the Accuracy of the Calypso Electromagnetic Localization System M. J. Murphy, R. Eidens, E. Vertatschitsch, J. Wright, Virginia Commonwealth University, Richmond, Va. #2994.  Clinical Experience with 4D PET/CT to Account for Intrafraction Motion in Radiation Oncology A. P. Shah, A. P. Santhanam, T. R. Willoughby, P. A. Kupelian, S. L. Meeks, M.D., Anderson Cancer Center Orlando, Orlando, Fla. #3041.  Clinical Use of Electromagnetic Guidance for Lung and Spine Radiation Therapy T. R. Willoughby, A. P. Shah, A. R. Forbes, R. R. Manon, P. A. Kupelian, S. L. Meeks, MD, Anderson Cancer Center Orlando, Orlando, Fla. #3053. 

About Calypso(R) Medical

Calypso(R) Medical Technologies, Inc. (“Calypso”) is a Seattle, WA-based privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon(R) electromagnetic transponders) to continuously, accurately, and objectively pinpoint and track the location of tumors for improved accuracy and management of radiation therapy delivery. Calypso addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion management during treatment. In addition, the Calypso(R) 4D Localization System’s non-ionizing electromagnetic guidance has been found to improve workflow efficiency and treatment room utilization. The technology is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, head, neck and other radiation therapy target organs. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed.




comments powered by Disqus